Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Breakthrough Breast Cancer Research Centre Pioneering Work Leads To Patient Trial Of New Generation Cancer Drug
The drug, called olaparib, specifically targets hereditary cancer caused by faulty BRCA1 and BRCA2 genes. The small scale patient trial has shown remarkable benefit for patients with breast, ovarian and prostate cancer.

Health Care Ads Leave Washington, Follow Lawmakers Home During Break
Roll Call reports that "several major industry stakeholders" will be "noticeably absent from the advertising airwaves over the July Fourth recess. Though they will continue to keep in touch with Members through meetings and grass roots, AARP, the American Medical Association, America"s Health Insurance Plans, the Federation of American Hospitals and AdvaMed all say they are sitting out this recess when it comes to advertising campaigns." Senate Finance Chairman Max Baucus, D-Mont., and White House aides have "warned that any groups that run ads attacking reform efforts before the bills have been crafted would lose their seats at the bargaining table," but the "advocacy ad floodgates" may "open shortly." Until then, "groups are working in a lower-profile way to get their messages across to Members," such as planning in-district meetings with Members and activating grassroots networks.
News of the day
Matrox, QUBYX And Datacolor Support 13-bit Calibration And Luminance Uniformity Correction For Medical Displays
Matrox Graphics Inc., the leading manufacturer of specialized graphics solutions, announced that QUBYX has integrated DATACOLOR"s Spyder3 colorimeter into its PerfectLUM medical display calibration software. In addition, the calibration software will also support the Matrox Xenia(tm) Series onboard 13-bit Gamma and Digital Luminance Correction (DLC(tm)) technology. By combining each company"s extensive and high quality solutions, Matrox has created a comprehensive package for the medical display and imaging marketplace that will ultimately save time, money, and improve efficiencies in patient care.
Health Insurance

Questioning The Credibility Of Some Published Clinical Trials

Randomised Controlled Trials (RCTs) are considered the "gold standard" research method for assessing new medical treatments. But research published in BioMed Central"s open access journal Trials shows that the design of a remarkable 93 percent of 2235 so-called RCTs published in some Chinese medical journals during 1994 to 2005 was flawed, casting doubt on the reliability of research that is likely to influence medical decision-makers. Researchers led by Taixiang Wu of the Chinese Cochrane Centre at Sichuan University, China and Ottawa Hospital Research Institute investigated clinical trials published in China between 1994 and 2005, searching the China National Knowledge Infrastructure (CNKI) electronic database for RCTs on 20 common diseases. To determine how many of these met recognised standards for randomly allocating participants to treatment groups, trained investigators interviewed the first or co-authors of 2235 trial reports by phone. Less than seven percent of self-described RCTs published in some Chinese medical journals meet criteria for authentic randomisation. The researchers looked at both conventional and traditional Chinese medicine trials, but there was no difference between these in terms of study authenticity rates. However, all RCTs of pre-market drug clinical trial were authentic, and RCTs conducted at hospitals affiliated with medical universities were more likely to be authentic than trials conducted at lower tier level three and level two hospitals. More than half of the trials at university-affiliated hospitals met RCT criteria, which means lower-tier hospital research is the least rigorous in design terms. "The fact that so many non-RCTs were published as RCTs reflected that peer-review needs to be improved and a Good Practice of Peer Review, including how to identify the authenticity of the study, urgently needs to be developed," says Wu. Misleading reporting of medical research is not unique to China. Studies labelled as RCTs are more likely to influence health policy-makers meaning falsely reported RCTs have the potential to mislead health care providers, consumers and policy-makers. The results of this study suggest authors of systematic reviews - articles that combine the results of multiple RCTs - need to be aware that RCTs in some Chinese journals may not be RCTs at all. The approximately 1100 medical journals now active in China are rapidly increasing their output of research reports, including many identified by their authors as RCTs. But these trials present mostly positive results (they favour the treatment being investigated), which can be influenced by inadequate randomisation of patients when designing the study. Notes: 1. Randomized trials published in some Chinese journals: How many are randomized? Taixiang Wu, Youping Li, Zhaoxiang Bian, Guanjian Liu and David Moher Trials (in press) http://www.trialsjournal.com/ Charlotte Webber BioMed Central


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009